Regina M.
Regina M. Fernicola, Fortson, GA US
Patent application number | Description | Published |
---|---|---|
20140192684 | SYSTEMS AND METHODS FOR SELECTIVE FILTERING OF INBOUND MOBILE COMMUNICATIONS - Various implementations of the disclosed technology relate to selectively filtering inbound communications. An example implementation may send filtered incoming calls directly to an alternate voicemail account based on a list of pre-approved contacts. Moreover, a user notification may not be provided at the time of receiving the incoming call. In another implementation, a response message indicating a user status may automatically be sent back to the sender of the inbound communication. In some implementations, selective filtering of inbound communications may be activated manually by a user, or automatically at a scheduled time, or responsive to a mobile device entering a threshold distance of a location. Discrete logs may be kept for each of selective filtered and allowed inbound communications. | 07-10-2014 |
Regina M. Sennello, Boulder, CO US
Patent application number | Description | Published |
---|---|---|
20090203609 | Use of IL-1 inhibitors for treating IL-1 mediated diseases - The invention relates to methods for treating or preventing arthritis. The method comprises administering to patients in need thereof therapeutically effective amounts of an IL-1 inhibitor and methotrexate. In a preferred embodiment, the IL-1 inhibitor is human recombinant IL-1ra and the methotrexate is N-[4-[(2,4-diamino-6-pteridinyl)methylamino]benzoyl]-L-glutamic acid. The invention also relates to pharmaceutical compositions containing an IL-1 inhibitor and methotrexate useful in such methods. | 08-13-2009 |
Regina M. Sennello, Oak Park, IL US
Patent application number | Description | Published |
---|---|---|
20120142028 | BIOLOGICAL MARKERS PREDICTIVE OF ANTI-CANCER RESPONSE TO EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITORS - The present invention provides diagnostic methods for predicting the effectiveness of treatment of a cancer patient with an EGFR kinase inhibitor. These methods are based on the surprising discovery that the effectiveness of treatment with an EGFR kinase inhibitor is predicted by whether a patient's tumor cells express a high or a low level of the biomarkers vimentin and E-cadherin, such that patients whose tumors express a high level of at least one of the biomarkers vimentin and E-cadherin have a longer overall survival and progression free survival than patients whose tumors express a low level of both vimentin and E-cadherin. The present invention further provides a method for treating tumors or tumor metastases in a patient, comprising the steps of diagnosing a patient's likely responsiveness to an EGFR kinase inhibitor by assessing whether tumor cells express a high level of at least one of the biomarkers vimentin and E-cadherin, and administering to said patient a therapeutically effective amount of an EGFR kinase inhibitor (e.g. erlotinib), particularly when effectiveness of the inhibitor is predicted. | 06-07-2012 |